Brief: Theriva Biologics Announces Orphan Medicinal Product Designation Granted By The European Commission To VCN-01 For The Treatment Of Retinoblastoma
16/10/2024 13:02
Oct 16 (Reuters) - Theriva Biologics Inc TOVX.A :
* THERIVA BIOLOGICS ANNOUNCES ORPHAN MEDICINAL PRODUCT
DESIGNATION
GRANTED BY THE EUROPEAN COMMISSION TO VCN-01 FOR THE TREATMENT
OF RETINOBLASTOMA
* THERIVA BIOLOGICS INC - EUROPEAN COMMISSION GRANTS ORPHAN
DESIGNATION TO THERIVA'S VCN-01 FOR RETINOBLASTOMA
Source text for Eikon: ID:nGNXbTmYjj
Further company coverage: TOVX.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Theriva Biologics
See all newsTheriva Biologics Q2 net loss narrows on lower R&D costs, expenses
Brief: Theriva™ Biologics Announces Upcoming Presentation Of Additional Data From The Virage Phase 2B Clinical Trial Of Vcn-01 In Metastatic Pancreatic Cancer At Aacr 2026 Annual Meeting
Brief: Theriva Biologics Licenses Syn-020 To Rasayana Therapeutics For Multiple Indications
Brief: Theriva Biologics Implements 32% Workforce Reduction - SEC Filing
Brief: Theriva™ Biologics Announces Presentation Of Data From Vcn-01 Retinoblastoma Phase 1 Clinical Trial At Asco 2025